Concepedia

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, E. Levchenko, Piotr Rutkowski, Jean-Jacques Grob, S.I. Korovin,

The Lancet Oncology · 2018 · 198 citations · 25 references

DOIFull text

Open access

Concepts

References

25

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text

, , +12

Final Version of 2009 AJCC Melanoma Staging and Classification

Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009 · 4.6K citations · Full text

, , +17

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

Pierre van der Bruggen, Catia Traversari, Patrick Chomez et al. · Science · 1991 · 3.5K citations

, , +17

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +17

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology · 1996 · 2.1K citations

, , +17